Ningbo Menovo Pharm Co Ltd Total Liabilities
Ningbo Menovo Pharm Co Ltd total liabilities. Based on the latest financial reports, Ningbo Menovo Pharm Co Ltd (603538) has total liabilities worth CN¥1.71 Billion CNY (≈ $249.85 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Ningbo Menovo Pharm Co Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ningbo Menovo Pharm Co Ltd (2011–2025)
Total liabilities of Ningbo Menovo Pharm Co Ltd from 2011 to 2025. This chart illustrates how Ningbo Menovo Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Ningbo Menovo Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Ningbo Menovo Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Naruida Technology Co. Ltd. Cl A
SHG:688522
|
China | CN¥341.60 Million |
|
Altareit
PA:AREIT
|
France | €2.67 Billion |
|
Capitol Federal Financial Inc
NASDAQ:CFFN
|
USA | $8.64 Billion |
|
Helix Energy Solutions Group Inc
NYSE:HLX
|
USA | $1.06 Billion |
|
TotalEnergies EP Gabon S.A.
PA:EC
|
France | €1.30 Billion |
|
International General Insurance Holdings Ltd
NASDAQ:IGIC
|
USA | $1.51 Billion |
|
LAMDA Development S.A.
AT:LAMDA
|
Greece | €3.10 Billion |
|
Cinda Real Estate Co Ltd
SHG:600657
|
China | CN¥55.04 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Ningbo Menovo Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ningbo Menovo Pharm Co Ltd (603538) total assets.
Liquidity & Leverage Metrics
Ningbo Menovo Pharm Co Ltd Total Liabilities Ratios Explained
Ningbo Menovo Pharm Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ningbo Menovo Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ningbo Menovo Pharm Co Ltd (2011–2025)
The table below shows the annual total liabilities of Ningbo Menovo Pharm Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.40 Billion ≈ $351.42 Million |
+1.77% |
| 2024-12-31 | CN¥2.36 Billion ≈ $345.31 Million |
+5.45% |
| 2023-12-31 | CN¥2.24 Billion ≈ $327.47 Million |
-0.37% |
| 2022-12-31 | CN¥2.25 Billion ≈ $328.69 Million |
+11.03% |
| 2021-12-31 | CN¥2.02 Billion ≈ $296.03 Million |
+55.59% |
| 2020-12-31 | CN¥1.30 Billion ≈ $190.27 Million |
+24.37% |
| 2019-12-31 | CN¥1.05 Billion ≈ $152.98 Million |
+12.30% |
| 2018-12-31 | CN¥930.92 Million ≈ $136.22 Million |
+165.08% |
| 2017-12-31 | CN¥351.19 Million ≈ $51.39 Million |
+56.59% |
| 2016-12-31 | CN¥224.27 Million ≈ $32.82 Million |
+23.34% |
| 2015-12-31 | CN¥181.83 Million ≈ $26.61 Million |
-54.83% |
| 2014-12-31 | CN¥402.54 Million ≈ $58.90 Million |
+6.71% |
| 2013-12-31 | CN¥377.24 Million ≈ $55.20 Million |
-3.02% |
| 2012-12-31 | CN¥389.00 Million ≈ $56.92 Million |
+17.35% |
| 2011-12-31 | CN¥331.50 Million ≈ $48.51 Million |
-- |
About Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more